SciFluour secures $5m in funding
SciFluor Life Sciences LLC, a Boston company focused on fluorination technology discovered at Harvard University, said that it has secured $5 million in first-round funding from Allied Minds, a private equity firm with offices in Boston and Los Angeles.
With a license from Harvard, SciFluor looks to commercialize technology that enables late-stage fluorination of pharmaceutical drug candidates and other commercial chemicals.
"Adding fluorine to organic molecules, such as pharmaceuticals, can significantly improve metabolic stability, potency, binding affinity, bioavailability, and blood-brain barrier penetration," the company said in a press release.
On its website, SciFluor notes that the technology it is licensing from Harvard's Office of Technology Development can "deliver the benefits of fluorine chemistry without the headaches of fluorination."